Advancements in biologics, inhaled formulations, and precision diagnostics are driving global growth in the alpha‑1 antitrypsin deficiency therapy market, meeting unmet needs in lung and liver complications. https://www.datamintelligence.com/research-report/alpha-1-antitrypsin-deficiency-therapy-market